Zymeworks (ZYME)
(Real Time Quote from BATS)
$13.68 USD
0.00 (0.00%)
Updated Nov 22, 2024 09:46 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZYME 13.68 0.00(0.00%)
Will ZYME be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
GSK (GSK) Q3 Earnings Surpass Estimates
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Other News for ZYME
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
Zymeworks Hold Rating: Balancing FDA Milestones with Market Valuation and Future Risks
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Zymeworks to Showcase Innovations at Investor Conferences